Methods for evaluating drug-resistance gene expression in the cancer patient
AssigneeOncoMEDx, Inc.
InventorMichael S. Kopreski
Life of this patent
Estimating the term…
Abstract
The methods of the invention detect in a qualitative or quantitative fashion drug-resistance RNA and DNA in blood plasma, serum, and other bodily fluids. The methods of the invention thereby enable the assessment of drug resistance in a neoplasm without the requirement of a tissue biopsy. The inventive methods are useful for the evaluation, monitoring, and selecting of drug treatment regimens, and for determining a predisposition for or prognosis of chemoresistant neoplastic disease.
Claims46
A method for detecting extracellular DNA from all or a portion of a drug resistance-associated gene in blood plasma or serum from a human or animal with a neoplasm in a brain of the human or animal for evaluating, monitoring, predicting, treating, or making a determination of drug-resistance in the neoplasm, the method comprising the steps of:
- a) extracting extracellular mammalian DNA from blood plasma or serum of a human or animal with a neoplasm in a brain of the human or animal;
- b) amplifying or signal amplifying a portion of the extracted DNA,
- wherein said fraction comprises extracellular DNA from a drug-resistance-associated gene, and wherein amplification is performed qualitatively or quantitatively using primers or probes specific for said DNA to produce an amplified product or signal;
- and
- c) detecting the amplified product or signal.
A method for detecting extracellular DNA from all or a portion of a drug resistance-associated gene in saliva from a human or animal with a neoplasm for evaluating, monitoring, predicting, treating, or making a determination of drug resistance in the neoplasm, the method comprising the steps of:
- a) extracting extracellular mammalian DNA from saliva of a human or animal with a neoplasm;
- b) amplifying or signal amplifying a portion of the extracted DNA, wherein said fraction comprises extracellular DNA from a drug-resistance-associated gene, and wherein amplification is performed qualitatively or quantitatively using primers or probes specific for said DNA to produce an amplified product or signal;
- and
- c) detecting the amplified product or signal.
A method of evaluating or monitoring drug resistance in a brain neoplasm without obtaining tissue from the neoplasm, the method comprising the steps of:
- a) extracting extracellular mammalian DNA from blood plasma or serum of a human or animal with a brain neoplasm;
- b) amplifying or signal amplifying a portion of the extracted DNA, wherein said fraction comprises extracellular DNA from a drug-resistance-associated gene, and wherein amplification is performed qualitatively or quantitatively using primers or probes specific for said DNA to produce an amplified product or signal;
- and
- c) detecting the amplified product or signal.
A method of evaluating or monitoring drug resistance in a neoplasm without obtaining tissue from the neoplasm, the method comprising the steps of:
- a) extracting extracellular mammalian DNA from saliva of a human or animal with a neoplasm;
- b) amplifying or signal amplifying a portion of the extracted DNA, wherein said fraction comprises extracellular DNA from a drug-resistance-associated gene, and wherein amplification is performed qualitatively or quantitatively using primers or probes specific for said DNA to produce an amplified product or signal;
- and
- c) detecting the amplified product or signal.
A method for detecting extracellular DNA from all or a portion of a drug resistance-associated gene, comprising the steps of extracting extracellular DNA from all or a portion of a drug-resistance-associated gene from blood plasma or serum from a human or animal with a neoplasm of the brain, hybridizing said DNA to a detectably-labeled probe specific for said DNA, and detecting hybridization of DNA from all or a portion of a drug-resistance-associated gene with the detectably-labeled probe.
A method for detecting extracellular DNA from all or a portion of a drug resistance-associated gene, comprising the steps of extracting extracellular DNA from saliva, hybridizing said DNA to a detectably-labeled probe specific or said DNA from all or a portion of a drug-resistance-associated gene, and detecting hybridization of DNA with the detectably-labeled probe.
Dependencies are inferred from the claim text.